Kancera AB (publ) today announces that Peter Selin has been appointed as Executive Vice President Corporate Development, responsible for business development, strategic partnerships and licensings. He will be part of the management team and report directly to the CEO.

Peter Selin is joining from Oasmia Pharmaceutical and the position as Chief Business Officer, responsible for company and product acquisitions, licensing, alliance management and commercialization. Peter has previously held various senior business development and operational positions, including as Vice President Business Operations at Inceptua Group and Vice President Corporate Development at Sobi. Before working within the pharmaceutical industry he worked as a management consultant at EY. Peter has a bachelor of science degree in business from Uppsala University.

”We are very glad to welcome Peter Selin to Kancera. He has extensive experience within international business development and partnering in the biotech and specialty pharma industry. Peter also has valuable expertise in the area of positioning rare disease products for partnering and we believe that this will be an important addition to our existing strong capabilities within research and development”, says Thomas Olin, CEO of Kancera AB.

”I am really looking forward to join Kancera and hope to contribute to the long term value building of the company as well as bring Kancera’s promising drug candidates all the way to the market and make them accessible for patients with high medical need”, says Peter Selin, newly appointed EVP Corporate Development at Kancera AB.

Peter Selin will take up his position as soon as practically possible but at the latest on May 1, 2022.

About Kancera AB (publ)
Kancera AB is developing a new class of drugs against inflammation and cancer. The company's drug candidates operate through a newly discovered control system for immune cells and cancer cells, the so-called fractalkine system. Kancera is studying its most advanced drug candidate KAND567 in two fully funded phase IIa clinical trials of heart, kidney and lung injuries caused by hyperinflammation. Top-line data from the phase IIa study in COVID patients were reported in November 2021. Recruitment of patients for the second phase IIa study, of inflammation after myocardial infarction, is expected to be completed in 2022. Kancera also conducts preclinical development of the drug candidate KAND145, which primarily is intended for the treatment of autoimmune diseases and cancer. Kancera also develops preclinical drug candidates against hematological, colorectal and ovarian cancers. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB (info@fnca.se, tel. 08-528 00 399) is the company's Certified Adviser.

For further information:
Thomas Olin
Chief Executive Officer, Kancera AB
Tel: +46-735-20 40 01

www.kancera.com